Cyclical psoriatic arthritis responding to anti-oestrogen therapy.
We report a patient with severe psoriatic arthritis in whom the severity of both the arthritis and psoriasis fluctuated with the menstrual cycle. These features failed to improve with standard therapy, but there was a prompt response to treatment which suppressed oestrogen secretion. Such treatment should be considered in patients with disabling cyclical changes in psoriatic arthritis.
Stevens
H P
HP
Department of Dermatology and Rheumatology, Royal Free Hospital and School of Medicine, London, U.K.
Ostlere
L S
LS
Black
C M
CM
Jacobs
H S
HS
Rustin
M H
MH
D000328:Adult; D015535:Arthritis, Psoriatic / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy*; D002064:Buserelin / Q000627:therapeutic use; D004717:Endometrium / Q000000981:diagnostic imaging; D004958:Estradiol / Q000097:blood; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008598:Menstruation / Q000502:physiology*; D011565:Psoriasis / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy; D013629:Tamoxifen / Q000627:therapeutic use; D014463:Ultrasonography
D004965:Estrogen Antagonists; D004966:Estrogens, Conjugated (USP); D013629:Tamoxifen; D017273:Goserelin; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D002064:Buserelin